List view / Grid view
Data presented at ECTRIMS highlight potential of early intervention with…
3 October 2013 | By Sanofi
Data presented at ECTRIMS highlight potential of early intervention with Aubagio to delay second clinical attack and reduce MRI lesion burden...
Genzyme announced positive top-line results from the TOPIC trial for…
25 April 2013 | By Sanofi
Genzyme announced positive top-line results from the TOPIC trial for AUBAGIO...
Cancer treatment faces a conundrum: a growing lack of therapeutics…
25 February 2013 | By Esther P. Black, College of Pharmacy and Markey Cancer Center, University of Kentucky
Cancer treatment faces a conundrum: a growing lack of therapeutics with lasting effects. The low hanging fruit of the medicinal chemistry orchard seems to have been picked, and modification of existing anti-cancer therapeutics has produced only incremental rewards[1]. Thus, both pharmaceutical companies and academic researchers are left searching for new…
In this Near Infrared Spectroscopy In-Depth Focus: Validation methodologies of…
In this Near Infrared Spectroscopy In-Depth Focus: Validation methodologies of near infrared spectroscopy methods in pharmaceutical applications; Evaluating the influence of hopper geometry on radial and axial concentration profiles in flowing granular mixtures...
AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing Multiple Sclerosis...
12 September 2012 | By Sanofi
AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing Multiple Sclerosis...
Biogen Idec and Elan Corporation, plc announced a global Phase…
26 January 2012 | By Biogen Idec
Biogen Idec and Elan Corporation, plc announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for SPMS...
